Oral GLP-1 Pill Cuts Insulin Needs and Blood Sugar in Type 2 Diabetes Trial

Type 2 diabetes management often hits a wall when standard medications fail to control blood sugar adequately. For patients already on basal insulin, the next step — intensifying insulin therapy — carries risks including weight gain and low blood sugar episodes. The ACHIEVE-5 trial, presented at the American Diabetes Association annual meeting, suggests a simpler path forward using an oral GLP-1 receptor agonist.

The trial tested orforglipron (Foundayo), a once-daily pill, added to basal insulin in adults with inadequately controlled type 2 diabetes, many of whom had lived with the disease for roughly 15 years. All participants underwent aggressive insulin titration targeting fasting glucose below 100 mg/dL. Those receiving orforglipron achieved this target with a smaller increase in daily insulin units compared to insulin alone — a meaningful efficiency gain.

On the primary endpoint, orforglipron delivered HbA1c reductions of 1.9% to 2.05% from a baseline of 8.5%, versus just 0.77% with insulin alone. The difference exceeded 1.2 percentage points. More patients on the combination reached aggressive HbA1c targets, including below 7%, 6.5%, and even 5.7%. Body weight dropped by approximately 6 kg in the orforglipron group, while insulin-only patients experienced slight weight gain.

Critically, the drug's safety profile was favorable. Nausea and vomiting occurred at rates typical for GLP-1 therapies, and hypoglycemia rates were not increased — they were numerically lower in the combination group than in the insulin-only arm.

For clinicians and patients, this positions oral orforglipron as a viable intensification option that avoids injections and may reduce insulin burden. Caveats include the video-based nature of the report and the need to review full trial data, including longer-term cardiovascular and renal outcomes, before broad clinical adoption.